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Abstract
Background: Germline mutations in BRCA1 or BRCA2 genes have been demonstrated to increase
the risk of developing breast cancer. Conversely, the impact of BRCA mutations on prognosis and
survival of breast cancer patients is still debated. In this study, we investigated the role of such
mutations on breast cancer-specific survival among patients from North Sardinia.
Methods: Among incident cases during the period 1997–2002, a total of 512 breast cancer
patients gave their consent to undergo BRCA mutation screening by DHPLC analysis and automated
DNA sequencing. The Hakulinen, Kaplan-Meier, and Cox regression methods were used for both
relative survival assessment and statistical analysis.
Results:  In our series, patients carrying a germline mutation in coding regions and splice
boundaries of BRCA1 and BRCA2 genes were 48/512 (9%). Effect on overall survival was evaluated
taking into consideration BRCA2 carriers, who represented the vast majority (44/48; 92%) of
mutation-positive patients. A lower breast cancer-specific overall survival rate was observed in
BRCA2 mutation carriers after the first two years from diagnosis. However, survival rates were
similar in both groups after five years from diagnosis. No significant difference was found for age of
onset, disease stage, and primary tumour histopathology between the two subsets.
Conclusion: In Sardinian breast cancer population, BRCA2 was the most affected gene and the
effects of BRCA2 germline mutations on patients' survival were demonstrated to vary within the
first two years from diagnosis. After a longer follow-up observation, breast cancer-specific rates of
death were instead similar for BRCA2 mutation carriers and non-carriers.
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Background
The breast cancer is a complex disease with high biologi-
cal heterogeneity and wide spectrum of responsiveness to
different treatments. The well-established prognostic fac-
tors currently used into the management of patients with
breast carcinoma include the disease stage (which takes
into account tumour size, axillary lymph node involve-
ment, and distant tumour dissemination) as well as the
histological type, the degree of differentiation (tumour
grade), the proliferation index, and the receptor status
[estrogen receptor (ER), progesterone receptor (PR), and,
recently, HER2] of the primary tumours [1]. Among them,
the expression levels of hormone receptors seem to better
predict the breast cancer response to different therapeutic
strategies. More in general, the assessment of some molec-
ular mechanisms responsible for the mammary tumouri-
genesis and studies on molecular profiling allowed to
identify several biomarkers which may be helpful to path-
ologically classify breast cancer lesions into subtypes with
different prognostic and clinico-pathologic behaviours
[2,3].
Mutations in the BRCA1 and BRCA2 tumour suppressor
genes have been associated with the breast cancer risk
among families with strong recurrence of the disease [4-
9]. Vast majority of studies has shown a highly increased
risk of developing breast cancer in BRCA1  or  BRCA2
mutation carriers [4-7] with also a greater incidence of a
second contra-lateral tumour [4,5,10]. However, majority
of breast cancers occur sporadically in individuals with lit-
tle or no family history, for whom no clear role of the
mutations in BRCA genes has emerged. Overall, BRCA
mutations are responsible for 30–60% of the hereditary
cases and have a prevalence of about 5% in the general
population and about 25% in the families with history of
breast cancer [9].
Analogously, several studies have investigated the possi-
ble effects of BRCA mutations on clinical and pathologic
characteristics of breast cancer as well as on prognosis and
survival rates of the patients, but the results were incon-
clusive. Some of these studies have demonstrated that
BRCA1 mutation carriers develop cancer with a high pro-
liferation index and low expression of estrogen receptors
[11,12]. Moreover, a higher proliferation index has been
reported in all breast cancer sporadic cases carrying a
BRCA  germline mutation (regardless of the gene
involved) in comparison to the patients with wild-type
BRCA [13-15]. Conversely, other authors observed no dif-
ference in histological tumour features among BRCA2-
positive familial cases and sporadic cases [16]. Regarding
the relationship with the survival, BRCA1 mutation carri-
ers showed either a poor prognosis in patients with nega-
tive lymph nodes [17] or a worse outcome in comparison
with  BRCA2-positive cases [18,19]. Other investigators
did not find any significant survival difference in BRCA
mutation carriers compared with non-carrier cases
[20,21]; moreover, breast cancer specific mortality rates
have been found similar for BRCA mutation carriers and
non-carriers in Jewish population [22]. Nevertheless, a
better assessment of the role on survival and prognosis
could be also important for women with a BRCA muta-
tion who face a decision between preventive surgery and
intensive surveillance.
In Sardinia, whose population is genetically homogene-
ous due to the fact that it is relatively isolated and with
high rate of inbreeding, the contribution of BRCA muta-
tions to the population incidence of breast cancer has
been evaluated by our group in recent past years [23-25].
Three deleterious BRCA  germline mutations have been
observed in about 15% families and in about 3% non-
familial breast cancer patients from North Sardinia
(BRCA2  mutations were the most prevalent BRCA
sequence variations and a single variant, BRCA2-
8765delAG, was the most recurrent mutation with a
founder effect in our population) [23-25]. In North Sar-
dinia, breast cancer represents the principal death-causing
malignancy, with an incidence rate quite comparable with
that observed in Western countries (standardized rate, 95
per 100.000 inhabitants per year); the median age of
onset for breast cancer among Sardinian women is 65
years [26]. Based on the existence of an official cancer reg-
istry, which has recorded all malignancies diagnosed into
the population of the province of Sassari from 1992 to
2003 [26], the objective of the present study was to inves-
tigate the relationship between the occurrence of BRCA
mutations and the main standardized prognostic factors
as well as the overall survival rates among breast cancer
patients from North Sardinia. Specifically, we compared
survival rates between BRCA2 mutation carriers and non-
carriers while adjusting for demographic and clinically-
recognized prognostic factors in a homogenous group of
Sardinian breast cancer patients.
Methods
Patients' selection
Among 1,835 incident cases during the period 1997–
2002 [with 140 (8%) tumour-specific deaths], we selected
all consecutive patients with histologically-proven diag-
nosis of malignant breast cancer (regardless of factors
which may influence prognosis: age, family history, dis-
ease stage, or type of treatment). Among them, 512
patients gave their consent to undergo genetic analysis for
detection of BRCA  mutations on germline DNA from
peripheral blood. For such cases, the collected informa-
tion included the disease stage at diagnosis, the expression
levels of estrogen and progesterone receptors, and the
occurrence of a second cancer. All information have been
verified through analysis of the hospital records; all cancer
diagnoses were confirmed by pathology reports.BMC Cancer 2009, 9:62 http://www.biomedcentral.com/1471-2407/9/62
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The study was reviewed and approved by the ethical
review boards of both Institutions (University of Sassari
and A.S.L.1 of Sassari).
Mutation screening
For the BRCA1 and BRCA2 genetic testing, all patients
were informed about the aims and limits of the mutation
analysis and blood samples were collected after obtaining
a patient's written consent (in any case, documentation of
counselling was carefully evaluated prior to genetic test-
ing). As previously described [23,24], genomic DNA sam-
ples were screened for mutations in BRCA1 and BRCA2
genes by a sequential combination of denaturing high-
performance liquid chromatography (DHPLC) analysis
and sequencing approach using an automated fluores-
cence-cycle sequencer (ABIPRISM 3100, Applied Biosys-
tems, Foster City, CA).
Statistical analysis
The following variables and categories were defined and
included in our analyses: pathological primary tumor size
(pT), pathological nodal status (pN), presence of distant
metastases (M), estrogen and progesteron receptor (ER
and PR, respectively) status, age at diagnosis, and overall
survival (calculated starting from the time of diagnosis to
the date of death or to the end of our follow-up observa-
tion on December 31, 2004). Receptor status was not
known in a fraction (about 30%) of the patients included
into the study.
The general mortality data were provided from official
regional sources, and in some cases were drawn from the
municipality rosters. The death probability was calculated
on the mortality rate basis and expressed as the probabil-
ity that an individual has, at beginning of the age class
considered, to die before going to the next age class. The
formula from life-table that assume a constant mortality
rate within a given period was applied [27]. In this case,
the age class was equal to one year, as required by the
Hakulinen method for calculation of relative survival
[28].
The five-year relative survival figures were also computed
following the Hakulinen method [28]; the 95% confi-
dence limits were calculated using the "eurocare " confi-
dence interval algorithm [29]. For the comparison of
survival probabilities within the various subgroups, the
cumulative relative survival adjusted for age was esti-
mated using the technique proposed by Brenner and col-
leagues [29].
The role of familiarity and BRCA status as genetic marker
in cause-specific survival was investigated by Kaplan-
Meier and Cox regression methods. All tests were com-
puted by Stata Software.
Results
Among the 512 breast cancer patients who gave their con-
sent to participate to the study, 103 (20%) had a family
history of breast cancer. Cases were classified as familial
when at least three affected members (considering first-
and second-degree relatives) were diagnosed with breast
cancer.
Mutation analysis for all coding regions and splice bound-
aries of BRCA1 and BRCA2 genes was performed as previ-
ously described [24]. Briefly, germline DNA from breast
cancer patients was screened by DHPLC analysis; all PCR
products presenting an abnormal denaturing profile in
comparison to the normal controls were sequenced using
an automated approach. Taking into consideration the
103 familial cases, 2 (2%) and 20 (19%) presented a
germline mutation in BRCA1 and BRCA2 genes, respec-
tively. Among the remaining 409 patients classified as
sporadic cases, 2 (0.5%) and 24 (6%) were found to carry
BRCA1  and  BRCA2  mutations, respectively. Overall,
patients carrying a BRCA mutation were 48/512 (9%). In
particular, BRCA1 mutations were detected in only 4/48
(8%) carriers, while BRCA2 mutations were identified in
vast majority of them (44/48; 92%), with the BRCA2-
8765delAG variant acting as a founder mutation [23-25].
Taking into account such a high preponderance of germ-
line mutations, only BRCA2-positive cases were consid-
ered for statistical correlations in our series.
The age of breast cancer onset was evaluated on the basis
of the mutation status; 23/44 (52%) BRCA2  mutation
positive and 188/464 (41%) BRCA2 mutation negative
patients were 50 years or younger at the time of diagnosis
(Table 1). Although the average age at diagnosis was
younger in patients carrying BRCA2  mutations [23/44
(52%) ≤ 50 years vs. 21/44 (48%) > 50 years] than in cases
with no detectable mutation [188/464 (41%) ≤ 50 years
vs. 276/464 (59%) > 50 years], such a difference was not
statistically significant. Using Pearson's Chi-Squared test,
the occurrence of a BRCA2 mutation was evaluated for
association with several pathological parameters: pT, pN,
M, or, when available, ER and PR. As shown in Table 2,
distribution of BRCA2 mutation carriers and non-carriers
was quite identical in the different subsets of patients
according to such pathological parameters (thus, no sta-
tistically significant correlation was observed – not
shown).
Taking into consideration the primary tumour morphol-
ogy, 348 (68%) ductal carcinomas, 62 (12%) lobular car-
cinomas, and 102 (20%) other histological types were
registered. The BRCA2 mutations were more prevalent in
lobular (7/62; 11%) than in ductal carcinomas (20/348;
6%); again, differences were not statistically significant.BMC Cancer 2009, 9:62 http://www.biomedcentral.com/1471-2407/9/62
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The five-year survival rate was 81% (80%, adjusted by
age) among BRCA2  mutation carriers and 91% (92%,
adjusted by age) among patients negative for BRCA2
mutations. Overall, the five-year relative survival rate for
breast cancer cases from our series was 85%. Evaluation of
the overall survival curves using the Kaplan-Meier method
indicated that patients carrying BRCA2  mutations pre-
sented a lower breast cancer-specific survival in compari-
son with those resulted negative for BRCA2 mutations,
within the first two years from diagnosis (Figure 1). Con-
sidering the entire observation period of five years from
diagnosis, the survival curves tended to merge with no sig-
nificant difference in outcome between the two groups
(Figure 1). Furthermore, no difference in survival among
familial and sporadic BRCA2 mutated cases was observed
(not shown). As estimated by Cox regression analysis, the
hazard ratio of patients positive for BRCA2 mutations was
found to be 0.7 (95% CI, 0.46–1.37), after adjustment by
age (Figure 2), and about 0.8 (95% CI, 0.48–1.62), after
adjustment by disease stage (Figure 3). Hazard ratios were
quite identical for both subsets when adjusted for tumour
grade (0.82; 95% CI, 0.53–0.98) and receptor status
(0.85; 95% CI, 0.64–0.97) (not shown).
Finally, multivariate Cox regression analysis was per-
formed considering all variables (pT, pN, M, ER, PR, and
BRCA2 mutations). The presence of metastases was the
only parameter with a significant impact on prognosis (p
Table 1: Distribution of patients according to BRCA2 mutation status and age of onset
Age Class BRCA2 mutation negative BRCA2 mutation positive Total
20 1 1
25 21 3
30 21 2 23
35 27 3 30
40 38 7 45
45 54 6 60
50 45 4 49
55 57 8 65
60 47 3 50
65 50 5 55
70 56 1 57
75 36 2 38
80 21 1 22
85 91 1 0
464 44 508
Overall survival curves based on the Kaplan-Meier method Figure 1
Overall survival curves based on the Kaplan-Meier 
method. Comparison between observed and predicted sur-
vival data for each subset of patients (with or without BRCA2 
mutations) is reported.
Relative five-year survival for breast cancer patients with or  without BRCA2 mutations (BRCA+/-), adjusted by age  according to Brenner Figure 2
Relative five-year survival for breast cancer patients 
with or without BRCA2 mutations (BRCA+/-), 
adjusted by age according to Brenner.BMC Cancer 2009, 9:62 http://www.biomedcentral.com/1471-2407/9/62
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< 0.001; hazard ratio, 8.939; 95% CI, 4.68–17.1). How-
ever, such a prognostic factor was not able to exert a con-
founding effect on mutation-based survival curves due to
the low number of patients with distant metastases (33/
508; 6%), who even showed a similar prevalence of
BRCA2 mutation-negative (30/464; 6%) and mutation-
positive (3/44; 7%) cases (see Table 2). No other associa-
tion between BRCA2 mutation status and overall survival
was observed for the remaining variables.
Discussion and conclusion
Breast cancers carrying BRCA1 or BRCA2 germline muta-
tions often occur in younger women as well as present a
high tumour grade and/or lack of expression of estrogen/
progesterone receptors (mostly, among BRCA1-positive
tumours) [11-16,30-32]. Although these features have
been associated with a poor prognosis, the relationship
between the occurrence of a BRCA1 or BRCA2 mutation
and the effect on overall survival is still controversial [17-
22,31,33-35].
In this study, we tried to clarify the role of BRCA muta-
tions on the outcome of breast cancer patients from North
Sardinia, where an official cancer registry is available [26].
In particular, we evaluated the 5-year survival rates among
women who had received the diagnosis of breast cancer
from 1997 to 2002 and gave their consent to undergo a
BRCA genetic testing. Among the 508 analyzed patients,
we assessed the breast cancer-specific survival rates for
women with (44 cases; 9%) or without (464 cases; 91%)
a BRCA2 germline mutation.
Using the Kaplan-Meier method, the survival rate of
patients with a positive BRCA2 genetic test was lower than
that of patients with negative genetic tests within the first
two years after diagnosis in our series. However, the two
survival curves tended to merge at the end of five years
from diagnosis (see Figure 1). This trend may indeed
account for the absence of significance of the Cox regres-
sion for BRCA2 status, due to the failure of proportional-
ity of hazards (a situation in which calculation of a total
hazard ratio with the Cox model is unsuitable). The rela-
Relative five-year survival for breast cancer patients accord- ing to (A) localized disease (stage 1–2) or (B) metastatic dis- ease (stage 3–4), and presence or absence of BRCA2  mutations (BRCA+/-) Figure 3
Relative five-year survival for breast cancer patients 
according to (A) localized disease (stage 1–2) or (B) 
metastatic disease (stage 3–4), and presence or 
absence of BRCA2 mutations (BRCA+/-).
Table 2: Distribution of BRCA2 cases according to the TNM and 
receptor status
Primary tumour size
BRCA2 mutation T1-2 T3-4 Total
Negative 421 91% 43 9% 464
Positive 41 93% 3 7% 44
Total 462 91% 46 9% 508
Lymph node metastasis
BRCA2 mutation Negative Positive Total
Negative 263 57% 201 43% 464
Positive 24 55% 20 45% 44
Total 287 56% 221 44% 508
Distant metastasis
BRCA2 mutation Absent Present Total
Negative 434 94% 30 6% 464
Positive 41 93% 3 7% 44
Total 475 94% 33 6% 508
Estrogen receptor
BRCA2 mutation Negative Positive Total
Negative 91 26% 257 74% 348
Positive 5 29% 12 71% 17
Total 96 26% 269 74% 365
Progesterone receptor
BRCA2 mutation Negative Positive Total
Negative 150 44% 189 56% 339
Positive 6 46% 7 54% 13
Total 156 44% 196 56% 352BMC Cancer 2009, 9:62 http://www.biomedcentral.com/1471-2407/9/62
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tive survival of the entire Sardinian series at five years
from diagnosis is slightly below the average survival rate
observed in breast cancer cases from the other Italian
regions [17]; moreover, it always remains lower in the
subset of BRCA2 mutation carriers than in that of BRCA2
mutation-negative patients, regardless the adjustments
according to the different prognostic parameters in multi-
variate analysis (see Figures 2 and 3). Indeed, the relative
survival seems to be worse in cases with positive BRCA2
genetic tests, even after adjustment for age of onset (which
represents one of the factors with the greatest influence on
cancer prognosis, according to the studies in other popu-
lations [34-36]). Although survival is also deeply influ-
enced by disease stage at the time of diagnosis, we
observed no significant difference between the two
BRCA2 subsets after stratification by stage.
Although our study has a number of limitations mainly
due to the fact that we identified only a limited fraction
(44/508; 9%) of mutation carriers and, thus, the sub-
group analyses relied on a small number of subjects, we
can conclude that a prolonged follow-up observation
seems to minimize the effect of the presence of BRCA2
germline mutations on prognosis among breast cancer
patients from Sardinian population.
Our findings are consistent with data recently reported in
Israeli women of Ashkenazi Jewish ancestry (who present
a high prevalence of hereditary breast cancer and BRCA
founder mutations) [22] as well as in a Dutch series of
BRCA1-associated breast carcinoma patients [37]. In both
studies, the breast cancer-specific survivals for carriers and
noncarriers of BRCA mutations were similar, even consid-
ering a longer period of observation (ten years) from diag-
nosis [22,37]. On the basis of these results, one could
speculate that additional factors may influence the prog-
nosis in such patients.
Search for prognostic factors in breast cancer patients is
still a challenge; several lifestyle and environmental risk
factors for breast cancer are being investigated. For exam-
ple, evidence have been recently found that an increase in
body mass index is associated with a poorer prognosis in
women receiving diagnosis of breast cancer [36]. Proba-
bly, further studies toward the comprehension of the
underlying interactions between all genetic and environ-
mental factors could really improve the classification of
the different subsets of patients who would be expected to
have better or worse prognosis as well as to be more or less
likely to respond to specific therapeutic interventions.
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